

Patient Information	Specimen Information	Client Information
████████████████████	██████████ ██████████	████████████████████ MAIL992
████████████████████	██████████ ██████████	████████████████████
████████████████████		████████████████████
████████████████████	██████████ ██████████	████████████████████
████████████████████	██████████ ██████████	████████████████████
████████████████████	██████████ ██████████	

COMMENTS: FASTING: YES
AN UPDATE OR CORRECTION HAS BEEN MADE TO NAME SPECIALIZED CO

Test Name	In Range	Out Of Range	Reference Range	Lab
IRON, TIBC AND FERRITIN PANEL				
IRON AND TOTAL IRON				EN
BINDING CAPACITY				
IRON, TOTAL		39 L	40-190 mcg/dL	
IRON BINDING CAPACITY	389		250-450 mcg/dL (calc)	
% SATURATION		10 L	16-45 % (calc)	
FERRITIN	25		16-154 ng/mL	EN
TESTOSTERONE, FREE (DIALYSIS) AND TOTAL (MS)				
TESTOSTERONE, TOTAL, MS	25		2-45 ng/dL	SLI

For additional information, please refer to
<http://education.questdiagnostics.com/faq/TotalTestosteroneLCMSMS>
(This link is being provided for informational/educational purposes only.)

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

TESTOSTERONE, FREE (DIALYSIS)				SLI
TESTOSTERONE, FREE	1.1		0.1-6.4 pg/mL	

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

LIPOPROTEIN (a)	<10		nmol/L	EN
-----------------	-----	--	--------	----

Verified by repeat analysis.

Reference Range <75

Risk:
Optimal <75
Moderate 75-125
High >125

Cardiovascular event risk category cut points (optimal, moderate, high) are based on Tsimika S. JACC 2017;69:692-711.

APOLIPOPROTEIN B	112 H		mg/dL	EN
-------------------------	--------------	--	-------	----

Reference Range < 90

Risk Category:
Optimal <90
Moderate 90-119
High > or = 120

Patient Information	Specimen Information	Client Information

Test Name	In Range	Out Of Range	Reference Range	Lab
-----------	----------	--------------	-----------------	-----

Cardiovascular event risk category cut points (optimal, moderate, high) are based on National Lipid Association recommendations-Jacobson TA et al. J of Clin Lipid. 2015; 9: 129-169 and Jellinger PS et al. Endocr Pract. 2017;23(Suppl 2):1-87.

COMPREHENSIVE METABOLIC PANEL				EN
-------------------------------	--	--	--	----

GLUCOSE	85		65-99 mg/dL	
---------	----	--	-------------	--

Fasting reference interval

UREA NITROGEN (BUN)	7		7-25 mg/dL	
CREATININE	0.57		0.50-1.10 mg/dL	
eGFR NON-AFR. AMERICAN	126		> OR = 60 mL/min/1.73m2	
eGFR AFRICAN AMERICAN	146		> OR = 60 mL/min/1.73m2	
BUN/CREATININE RATIO	NOT APPLICABLE		6-22 (calc)	
SODIUM	136		135-146 mmol/L	
POTASSIUM	4.3		3.5-5.3 mmol/L	
CHLORIDE	104		98-110 mmol/L	
CARBON DIOXIDE	24		20-32 mmol/L	
CALCIUM	9.6		8.6-10.2 mg/dL	
PROTEIN, TOTAL	6.9		6.1-8.1 g/dL	
ALBUMIN	4.3		3.6-5.1 g/dL	
GLOBULIN	2.6		1.9-3.7 g/dL (calc)	
ALBUMIN/GLOBULIN RATIO	1.7		1.0-2.5 (calc)	
BILIRUBIN, TOTAL	1.1		0.2-1.2 mg/dL	
ALKALINE PHOSPHATASE	55		31-125 U/L	
AST	17		10-30 U/L	
ALT	7		6-29 U/L	
HEMOGLOBIN A1c	4.9		<5.7 % of total Hgb	EN

For the purpose of screening for the presence of diabetes:

<5.7%	Consistent with the absence of diabetes
5.7-6.4%	Consistent with increased risk for diabetes (prediabetes)
> or =6.5%	Consistent with diabetes

This assay result is consistent with a decreased risk of diabetes.

Currently, no consensus exists regarding use of hemoglobin A1c for diagnosis of diabetes in children.

According to American Diabetes Association (ADA) guidelines, hemoglobin A1c <7.0% represents optimal control in non-pregnant diabetic patients. Different metrics may apply to specific patient populations. Standards of Medical Care in Diabetes(ADA).

URIC ACID	4.7		2.5-7.0 mg/dL	EN
Therapeutic target for gout patients: <6.0 mg/dL				

TSH	0.80		mIU/L	EN
-----	------	--	-------	----

Patient Information	Specimen Information	Client Information

Test Name	In Range	Out Of Range	Reference Range	Lab
-----------	----------	--------------	-----------------	-----

> or = 20 Years 0.40-4.50

Pregnancy Ranges

First trimester	0.26-2.66
Second trimester	0.55-2.73
Third trimester	0.43-2.91

T4, FREE	1.0	0.8-1.8 ng/dL	EN
T3, FREE	2.6	2.3-4.2 pg/mL	EN
IGF 1, LC/MS	149	63-373 ng/mL	EZ
Z SCORE (FEMALE)	-0.2	-2.0 - +2.0 SD	

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

CBC (INCLUDES DIFF/PLT)			EN
WHITE BLOOD CELL COUNT	7.4	3.8-10.8 Thousand/uL	
RED BLOOD CELL COUNT	4.40	3.80-5.10 Million/uL	
HEMOGLOBIN	12.6	11.7-15.5 g/dL	
HEMATOCRIT	37.5	35.0-45.0 %	
MCV	85.2	80.0-100.0 fL	
MCH	28.6	27.0-33.0 pg	
MCHC	33.6	32.0-36.0 g/dL	
RDW	11.9	11.0-15.0 %	
PLATELET COUNT	237	140-400 Thousand/uL	
MPV	11.0	7.5-12.5 fL	
ABSOLUTE NEUTROPHILS	5950	1500-7800 cells/uL	
ABSOLUTE LYMPHOCYTES	1066	850-3900 cells/uL	
ABSOLUTE MONOCYTES	348	200-950 cells/uL	
ABSOLUTE EOSINOPHILS		15-500 cells/uL	
ABSOLUTE BASOPHILS	30	0-200 cells/uL	
NEUTROPHILS	80.4	%	
LYMPHOCYTES	14.4	%	
MONOCYTES	4.7	%	
EOSINOPHILS	0.1	%	
BASOPHILS	0.4	%	
URINALYSIS, COMPLETE			EN
COLOR	YELLOW	YELLOW	
APPEARANCE	CLEAR	CLEAR	
SPECIFIC GRAVITY	1.008	1.001-1.035	
PH	6.0	5.0-8.0	
GLUCOSE	NEGATIVE	NEGATIVE	
BILIRUBIN	NEGATIVE	NEGATIVE	
KETONES	NEGATIVE	NEGATIVE	
OCCULT BLOOD	NEGATIVE	NEGATIVE	
PROTEIN	NEGATIVE	NEGATIVE	
NITRITE	NEGATIVE	NEGATIVE	
LEUKOCYTE ESTERASE		NEGATIVE	
WBC	0-5	< OR = 5 /HPF	
RBC	NONE SEEN	< OR = 2 /HPF	
SQUAMOUS EPITHELIAL CELLS	NONE SEEN	< OR = 5 /HPF	